AI Article Synopsis

  • The study investigates the effects of montelukast (MLK), a cysteinyl leukotriene receptor antagonist, on neuroinflammation and metabolic functions in a rat model of Huntington's disease induced by quinolinic acid (QA).
  • Rat subjects were divided into groups receiving either MLK or a vehicle, monitored through MRI and PET imaging over 14 days and later at 4 months to assess neuroinflammatory responses and metabolic changes.
  • Results showed that while MLK did not significantly reduce QA-induced lesions or inflammation markers, it did attenuate some signs of neuroinflammation and altered metabolic connectivity in the brain regions measured.

Article Abstract

Background: One intrastriatal administration of quinolinic acid (QA) in rats induces a lesion with features resembling those observed in Huntington's disease. Our aim is to evaluate the effects of the cysteinyl leukotriene receptor antagonist montelukast (MLK), which exhibited neuroprotection in different preclinical models of neurodegeneration, on QA-induced neuroinflammation and regional metabolic functions.

Methods: The right and left striatum of Sprague Dawley and athymic nude rats were injected with QA and vehicle (VEH), respectively. Starting from the day before QA injection, animals were treated with 1 or 10 mg/kg of MLK or VEH for 14 days. At 14 and 30 days post-lesion, animals were monitored with magnetic resonance imaging (MRI) and positron emission tomography (PET) using [F]-VC701, a translocator protein (TSPO)-specific radiotracer. Striatal neuroinflammatory response was measured post-mortem in rats treated with 1 mg/kg of MLK by immunofluorescence. Rats treated with 10 mg/kg of MLK also underwent a [F]-FDG PET study at baseline and 4 months after lesion. [F]-FDG PET data were then used to assess metabolic connectivity between brain regions by applying a covariance analysis method.

Results: MLK treatment was not able to reduce the QA-induced increase in striatal TSPO PET signal and MRI lesion volume, where we only detected a trend towards reduction in animals treated with 10 mg/kg of MLK. Post-mortem immunofluorescence analysis revealed that MLK attenuated the increase in striatal markers of astrogliosis and activated microglia in the lesioned hemisphere. We also found a significant increase in a marker of anti-inflammatory activity (MannR) and a trend towards reduction in a marker of pro-inflammatory activity (iNOS) in the lesioned striatum of MLK-compared to VEH-treated rats. [F]-FDG uptake was significantly reduced in the striatum and ipsilesional cortical regions of VEH-treated rats at 4 months after lesion. MLK administration preserved glucose metabolism in these cortical regions, but not in the striatum. Finally, MLK was able to counteract changes in metabolic connectivity and measures of network topology induced by QA, in both lesioned and non-lesioned hemispheres.

Conclusions: Overall, MLK treatment produced a significant neuroprotective effect by reducing neuroinflammation assessed by immunofluorescence and preserving regional brain metabolism and metabolic connectivity from QA-induced neurotoxicity in cortical and subcortical regions.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9923670PMC
http://dx.doi.org/10.1186/s12974-023-02714-zDOI Listing

Publication Analysis

Top Keywords

treated 10 mg/kg
12
10 mg/kg mlk
12
metabolic connectivity
12
mlk
10
animals treated
8
rats treated
8
[f]-fdg pet
8
4 months lesion
8
mlk treatment
8
increase striatal
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!